Millennium Management’s Aclaris Therapeutics ACRS Stock Holding History

Millennium Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57,400	Closed	-$393K	–	6018
2023 Q3	$393K	Buy	57,400 +7,400	+15%	+$63.2K	﹤0.01%	4790
2023 Q2	$519K	Hold	50,000	–	–	﹤0.01%	4513
2023 Q1	$405K	Buy	+50,000	New	+$635K	﹤0.01%	4729
2022 Q1	–	Sell	-50,000	Closed	-$727K	–	6830
2021 Q4	$727K	Hold	50,000	–	–	﹤0.01%	4720
2021 Q3	$900K	Buy	+50,000	New	+$802K	﹤0.01%	4805

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management's ACRS Position: Q1 2026 in Review

Millennium Management reduced its Aclaris Therapeutics (ACRS) stake by 28% in Q1 2026, selling an estimated $1M and leaving 756,127 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3522.

Millennium Management first reported a position in ACRS in Q1 2017 and has held it in 32 quarters since. The position peaked at $13.5M in Q3 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Millennium Management held 756,127 shares of Aclaris Therapeutics worth $2.84M as of Q1 2026.
Millennium Management sold 297,119 Aclaris Therapeutics shares in Q1 2026, an estimated $1M.
Aclaris Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3522 holding.
Millennium Management first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 32 quarters since.
Millennium Management's Aclaris Therapeutics position peaked at $13.5M in Q3 2023.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.